A 12-Step Desensitization Protocol for Calaspargase Pegol-mknl.
Minh H N Nguyen, Amanda Memken, Panida Sriaroon, Monica Hajirawala, Jennifer L R Mayer
Author Information
Minh H N Nguyen: Division of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Amanda Memken: Department of Pharmacy (AM), Pediatric Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, FL.
Panida Sriaroon: Division of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Monica Hajirawala: Division of Allergy and Immunology (MN, PS, MH), Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL.
Jennifer L R Mayer: Cancer and Blood Disorders Institute (JM), Johns Hopkins All Children's Hospital, St. Petersburg, FL.
Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As a bacteria-derived enzyme, asparaginase is highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction of pegaspargase, a PEGylated version of -derived asparaginase. Asparaginase (recombinant)-rywn (recombinant Erwinia) is an alternative for those with HSRs to pegaspargase. Here, we describe an 11-year-old boy with relapsed ALL who developed HSRs to both pegaspargase and recombinant Erwinia. This is the report of a novel desensitization protocol for calaspargase pegol-mknl (calaspargase) with no adverse events and adequate serum asparaginase activity.
